OUR PARTNERS AND COLLABORATORS

Medicenna Therapeutics, Inc (“Medicenna”) has licensed rights to patents and intellectual property related to Superkine™ and Empowered Cytokine™ platforms from:

  • Stanford University
  • National Institute of Health
  • Hebrew University of Jerusalem

In addition, Medicenna maintains a Collaborative Research and Development Agreement (“CRADA”) with the Center for Biologics Evaluation and Research (CBER) at the USFDA. The potential of the IL-4 Empowered Cytokines™ (IL4-ECs) combines the intellectual talent of scientists at Stanford University, the USFDA and the Hebrew University of Jerusalem.


PARTNERING OPPORTUNITIES

In addition to the lead clinical asset, MDNA55, our early stage pipeline of IL4-Empowered Cytokines™ (IL4-ECs), namely MDNA56 and MDNA57 are also available for collaborative opportunities.

MULTIPLE “PIPELINE IN A PRODUCT” OPPORTUNITIES

Product Initial Opportunity Stage Line Extensions
MDNA55(cpIL4-PE) Recurrent GBM; Metastatic Brain Cancer Clinical Phase 2 Newly diagnosed GBM, pediatric CNS cancers; localized delivery to urological cancers
MDNA56 (human pro-apoptotic Type 1 IL-4 fusion) Second or third line refractory CLL Pre-Clinical First or second line blood cancers such as NHL and Follicular Lymphoma
MDNA57 (human pro-apoptotic Type 2 IL-4 fusion) Target the immunosuppressive tumor micro-environment; Pancreatic adenocarcinoma Pre-Clinical Mesothelioma; NSCLC; Head and Neck Cancer; Biliary Tract Carcinoma; Colorectal Cancer, Breast Cancer;

For more information on partnering opportunities, please email: Dr. ShafiqueFidai

Top